Genkyotex, a pharma company based in Geneva, is the leading developer of NOX inhibitors. The Company is developing first-in-class, small molecule therapeutics that selectively inhibit NOX enzymes. Genkyotex has built a pipeline of NOX inhibitors for different diseases led by the NOX1&4 inhibitor GKT137831, which is in advanced clinical development in several blockbuster indications.
Genticel has acquired 100% of the shares in Genkyotex and issued new shares in consideration of the deal resulting Genkyotex’s shareholders taking an 80% stake in Genticel. Total deal value EUR 150m.
Learn more on https://www.genkyotex.com